Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:SRPT NYSE:TEVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeSRPTSarepta Therapeutics$16.96-0.9%$20.00$10.41▼$43.92$1.81B0.263.13 million shs2.02 million shsTEVATeva Pharmaceutical Industries$34.21-0.3%$31.76$14.99▼$37.35$39.46B0.867.60 million shs4.60 million shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceSRPTSarepta Therapeutics-0.93%-9.21%-17.99%-10.17%-57.65%TEVATeva Pharmaceutical Industries-0.32%-3.17%+9.30%-0.10%+106.37%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeSRPTSarepta Therapeutics$16.96-0.9%$20.00$10.41▼$43.92$1.81B0.263.13 million shs2.02 million shsTEVATeva Pharmaceutical Industries$34.21-0.3%$31.76$14.99▼$37.35$39.46B0.867.60 million shs4.60 million shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceSRPTSarepta Therapeutics-0.93%-9.21%-17.99%-10.17%-57.65%TEVATeva Pharmaceutical Industries-0.32%-3.17%+9.30%-0.10%+106.37%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceSRPTSarepta Therapeutics 2.11Hold$27.1760.22% UpsideTEVATeva Pharmaceutical Industries 2.80Moderate Buy$41.7822.14% UpsideCurrent Analyst Ratings BreakdownLatest SRPT and TEVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)5/6/2026TEVATeva Pharmaceutical Industries BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$38.00 ➝ $40.004/30/2026TEVATeva Pharmaceutical Industries JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$35.00 ➝ $40.004/30/2026TEVATeva Pharmaceutical Industries UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$36.00 ➝ $42.004/30/2026TEVATeva Pharmaceutical Industries Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$41.00 ➝ $42.004/30/2026TEVATeva Pharmaceutical Industries Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$42.00 ➝ $45.004/22/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)4/20/2026TEVATeva Pharmaceutical Industries Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/16/2026SRPTSarepta Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell4/9/2026TEVATeva Pharmaceutical Industries Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$38.00 ➝ $42.004/7/2026SRPTSarepta Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$18.00 ➝ $19.00(Data available from 5/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookSRPTSarepta Therapeutics$2.20B0.81N/AN/A$14.26 per share1.19TEVATeva Pharmaceutical Industries$17.26B2.28$3.72 per share9.20$7.16 per share4.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateSRPTSarepta Therapeutics-$713.41M-$0.96N/A7.410.19-2.94%7.56%2.94%8/5/2026 (Estimated)TEVATeva Pharmaceutical Industries$1.41B$1.3325.7211.253.329.01%43.53%8.19%7/29/2026 (Estimated)Latest SRPT and TEVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026SRPTSarepta Therapeutics$0.9760$3.16+$2.1840$2.88$474.16 million$730.80 million4/29/2026Q1 2026TEVATeva Pharmaceutical Industries$0.50$0.53+$0.03$0.31$3.79 billion$3.98 billion3/31/2026Q1 2026TEVATeva Pharmaceutical IndustriesN/A$0.53N/A$0.31N/A$3.98 billion2/25/2026Q4 2025SRPTSarepta Therapeutics-$0.87-$3.58-$2.71-$3.93$390.95 million$442.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthSRPTSarepta TherapeuticsN/AN/AN/AN/AN/ATEVATeva Pharmaceutical IndustriesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioSRPTSarepta Therapeutics0.564.632.62TEVATeva Pharmaceutical Industries1.701.010.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipSRPTSarepta Therapeutics86.68%TEVATeva Pharmaceutical Industries54.05%Insider OwnershipCompanyInsider OwnershipSRPTSarepta Therapeutics6.90%TEVATeva Pharmaceutical Industries0.54%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableSRPTSarepta Therapeutics1,372105.58 million98.29 millionOptionableTEVATeva Pharmaceutical Industries33,9501.15 billion1.14 billionOptionableSRPT and TEVA HeadlinesRecent News About These CompaniesTeva Pharmaceutical Industries Ltd. $TEVA Stock Position Decreased by Pinnbrook Capital Management LP2 hours ago | marketbeat.comThe European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in AdultsMay 21 at 5:25 PM | finance.yahoo.comThe European Medicines Agency Accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in AdultsMay 21 at 12:30 PM | globenewswire.comIFP Advisors Inc Acquires 137,580 Shares of Teva Pharmaceutical Industries Ltd. $TEVAMay 21 at 6:08 AM | marketbeat.comTeva TD Findings Highlight Underdiagnosis And Shape Neuroscience Growth StoryMay 20 at 11:21 AM | finance.yahoo.comTeva Pharmaceutical Industries (NYSE:TEVA) EVP Sells $5,457,268.11 in StockMay 20 at 5:35 AM | insidertrades.comTeva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Gabelli Funds LLCMay 20 at 3:36 AM | marketbeat.comVistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical OfficerMay 19 at 12:37 PM | finance.yahoo.comTeva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?May 19 at 12:37 PM | finance.yahoo.comTeva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?May 19 at 12:26 PM | zacks.comEliyahu Sharon Kalif Sells 153,251 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) StockMay 19 at 4:01 AM | americanbankingnews.comTeva Pharmaceutical Industries Ltd: Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite ...May 18, 2026 | finanznachrichten.deTeva Pharmaceutical Industries Ltd: Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth ExecutionMay 18, 2026 | finanznachrichten.deTeva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread ImpactMay 18, 2026 | finance.yahoo.comFitch Upgrades Teva to Investment Grade Amid Pivot to Growth ExecutionMay 18, 2026 | finance.yahoo.comFitch Upgrades Teva to Investment Grade Amid Pivot to Growth ExecutionMay 18, 2026 | financialpost.comFFitch Upgrades Teva to Investment Grade Amid Pivot to Growth ExecutionMay 18, 2026 | globenewswire.comTeva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread ImpactMay 18, 2026 | globenewswire.comTeva Pharmaceutical (TEVA) Reports Q1 Beat, Plans Amylyx DealMay 16, 2026 | finance.yahoo.comTeva Pharmaceutical Industries Ltd. $TEVA Shares Purchased by Bessemer Group Inc.May 16, 2026 | marketbeat.comPhoenix Financial Ltd. Sells 208,113 Shares of Teva Pharmaceutical Industries Ltd. $TEVAMay 15, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSRPT and TEVA Company DescriptionsSarepta Therapeutics NASDAQ:SRPT$16.96 -0.16 (-0.93%) Closing price 05/21/2026 04:00 PM EasternExtended Trading$17.11 +0.15 (+0.88%) As of 08:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.Teva Pharmaceutical Industries NYSE:TEVA$34.21 -0.11 (-0.33%) Closing price 05/21/2026 03:59 PM EasternExtended Trading$34.31 +0.10 (+0.30%) As of 08:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Intuit's Great SaaS Reset: Fired By AI Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish Target Shows Strengths, But Analysts Want to See More Freight Boom: The Hormuz Blockade Payday TJX Companies Fires on All Cylinders With 9% Revenue Growth Analog Devices Provides Much-Needed Pullback: How Low Can It Go? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
